Is vabysmo for amd?

Is Vabysmo used for AMD?

Vabysmo (faricimab) is used to treat age-related macular degeneration (AMD), including both:
- Wet (neovascular) AMD
- “Dry” AMD in people with geographic atrophy (GA) (depending on country labeling and eligibility criteria)

What kind of AMD does Vabysmo treat?

AMD comes in different forms. Vabysmo is best known for wet AMD (neovascular AMD). It is also used for geographic atrophy associated with dry AMD, which affects the central retina and can reduce vision.

How is Vabysmo given for AMD?

Vabysmo is administered as an intravitreal injection (injected into the eye). Treatment schedules vary by response and the specific regimen used by the clinician.

Is it the same as anti-VEGF treatment like Lucentis or Eylea?

Wet AMD treatments commonly target VEGF (a protein that drives abnormal blood vessel growth). Vabysmo is an antibody designed to work against more than one pathway involved in disease activity, so it is used as an intravitreal therapy in place of, or as an alternative to, VEGF-only options depending on the patient and prescribing guidelines.

Sources

1. DrugPatentWatch.com – Vabysmo (faricimab) patent and drug information